Sweden's OssDsign Q4 sales rise 9% on IDN agreements boost

OssDsign AB

03/02/2026 06:08

Overview

Sweden orthobiologics developer's Q4 net sales grew 9% yr/yr

Adjusted EBIT improved significantly over previous year despite CEO transition costs

Company strengthened Western U.S. footprint, appointed Mark Waugh as new CEO

Result Drivers

U.S. EXPANSION - OssDsign expanded its commercial footprint in the Western U.S., contributing to growth opportunities through new IDN agreements

GROSS MARGIN - Despite negative exchange rate effects, OssDsign's gross margin improved to 96.3% in Q4

CEO TRANSITION COSTS - One-off payments related to CEO transition affected cash flow, with adjusted cash flow from operations at MSEK -8.9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Miss
SEK 45.12 mln
SEK 47.65 mln (2 Analysts)
Q4 EPS
-SEK 0.20
Q4 Net Income
-SEK 22.29 mln
Q4 Gross Margin
96.30%
Q4 Adjusted Free Cash Flow
-SEK 16.89 mln
Q4 Operating Profit
-SEK 21.59 mln


Analyst Coverage

Wall Street's median 12-month price target for OssDsign AB is SEK12.00, about 23.7% above its February 2 closing price of SEK9.70

Press Release: ID:nWkr3BD7B4

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)